TotalMarketCap

Inmune Bio

INMBNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$36.841 M

$1.19 -10.53%

Close of 6 Nov 2026

As of 6 Nov 2026, Inmune Bio (INMB) has a market capitalization of $36.8M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$50.0K

#3586 by revenue

Earnings

-$46.0M

Loss-making

Shares outstanding

30,959,079

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #129LeonaBioLONA$40.8M
  2. #130ExozymesEXOZ$38.2M
  3. #131Inmune BioINMB$36.8M
  4. #132Pelthos TherapeuticsPTHS$36.7M
  5. #133ElutiaELUT$34.7M

What if Inmune Bio were worth as much as…

Open the what-if tool →

Gold $28.2T

$912,070.86

Per share 766,446× higher

Bitcoin $1.53T

$49,350.57

Per share 41,471× higher

Apple $5.02T

$162,013.30

Per share 136,146× higher

Or at a round number

$50.0M$100.0M$200.0M$500.0M

Where these numbers come from

Share counts and financials for Inmune Bio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.